



## SAFETY DATA SHEET

Section 1: Identification	
<b>Material</b>	<b>Lenalidomide Capsules 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg</b>
<b>Recommended use</b>	Pharmaceutical product
<b>Manufacturer</b>	<b>Hetero Labs Limited Unit V,</b> Survey. No 439, 440, 441 & 458, Polepally Village, Mahabubnagar, Telangana 509301 INDIA
<b>Distributor</b>	<b>Camber Pharmaceuticals, Inc.,</b> Piscataway, NJ 08854
Section 2: Hazard(s) Identification	
<b>Classification:</b> Classification of the substance or mixture	Drugs in the finished state and intended for the final user are not subject to labeling in the US. Please refer the prescribing/packaging information.
<b>GHS Classification</b>	STOT-R1: H372; RT1B: H360D; Carc2: H351
Section 3: Composition/Information on Ingredients	
<b>Ingredients</b>	<b>CAS</b>
Lenalidomide	191732-72-6
Anhydrous Lactose	63-42-3
Croscarmellose Sodium	74811-65-7
Magnesium Stearate	557-04-0
Microcrystalline Cellulose	9004-34-6
Section 4: First-Aid Measures	
<b>Ingestion</b>	Do not induce vomiting unless directed by medical personnel. Do not give anything to drink unless directed by medical personnel. Never give anything by mouth to an unconscious person. Notify medical personnel and supervisor.
<b>Inhalation</b>	Immediately move exposed subject to fresh air. If not breathing, give artificial respiration. If breathing is labored, administer oxygen. Immediately notify medical personnel and supervisor.



<b>Skin Contact</b>	Wash exposed area with soap and water and remove contaminated clothing/shoes. If irritation occurs or persists, notify medical personnel and supervisor.
<b>Eye Contact</b>	If easy to do, remove contact lenses, if worn. Immediately flush eyes with copious quantities of water for at least 15 minutes. If irritation occurs or persists, notify medical personnel and supervisor.
<b>Section 5: Fire-Fighting Measures</b>	
<b>Suitable Extinguishing Media</b>	Use water spray (fog), foam, dry powder, or carbon dioxide, as appropriate for surrounding fire and materials.
<b>Unsuitable Extinguishing Media</b>	None known.
<b>Specific hazards arising from the the substance or mixture</b>	No information identified. May emit toxic fumes of carbon monoxide, carbon dioxide, and oxides of nitrogen.
<b>Flammability/ Explosivity</b>	Not considered to be a fire hazard. No explosivity data available. High concentrations of finely divided airborne organic particles can potentially explode if ignited.
<b>Protective equipment and precautions for firefighters</b>	Wear full protective clothing and a self-contained breathing apparatus with a full facepiece operated in the pressure demand or other positive pressure mode. Decontaminate all equipment after use.
<b>Section 6: Accidental Release Measures</b>	
<b>Personal precautions</b>	If product is released or spilled, take proper precautions to minimize exposure by using appropriate personal protective equipment (see Section 8). Area should be adequately ventilated. Do not breathe dust.
<b>Environmental Precautions</b>	Do not empty into drains. Avoid release to the environment.
<b>Methods and materials for containment and cleaning up</b>	If capsules are broken or crushed, DO NOT RAISE DUST. Surround spill or powder with absorbents and



	place a damp cloth or towel over the area to minimize entry of powder into the air. Add excess liquid to allow the material to enter solution. Capture remaining liquid onto spill absorbents. Place spill materials into a leak-proof container suitable for disposal in accordance with applicable waste disposal regulations. Decontaminate the area twice.
--	--

**Section 7: Handling and Storage**

<b>Storage</b>	Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].
----------------	--

**Section 8: Exposure Controls/Personal Protection**

<b>Engineering Controls</b>	None required for normal handling of packaged product. If handling bulk capsules or capsules are crushed or broken: Control exposures to below the OEL (if available). Otherwise, selection and use of containment devices and personal protective equipment should be based on a risk assessment of exposure potential.  Open handling should not be performed when handling potent substances, or substances of unknown toxicity. Material should be handled inside a closed process, ventilated enclosure, isolator or device of equivalent or better control that is suitable for dusts and/or aerosols.
<b>Personal protection equipment</b>	
<b>Eye/face protection</b>	Wear safety glasses with side shields, chemical splash goggles, or full face shield, if necessary. Base the choice of protection on the job activity and potential for contact with eyes or face. An emergency eye wash station should be available.
<b>Skin protection</b>	Wear appropriate gloves, lab coat, or other protective overgarment if skin contact is likely. Base the choice of skin protection on the job activity, potential for skin contact and solvents and reagents in use.
<b>Hand protection</b>	Wear nitrile or other impervious gloves if skin contact is possible. Double gloves should be considered. When the material is dissolved or suspended in an organic solvent,



	wear gloves that provide protection against the solvent.
<b>Environmental Exposure Controls</b>	Avoid release to the environment and operate within closed systems wherever practicable. Air and liquid emissions should be directed to appropriate pollution control devices. In case of spill, do not release to drains. Implement appropriate and effective emergency response procedures to prevent release or spread of contamination and to prevent inadvertent contact by personnel.
<b>Other protective measures</b>	Wash hands in the event of contact with this substance, especially before eating, drinking or smoking. Protective equipment is not to be worn outside the work area (e.g., in common areas or out-of-doors).

### Section 9: Physical and Chemical Properties

<b>Physical Form</b>	Capsule
<b>Description</b>	<p>Lenalidomide Capsules 2.5 mg: Pink opaque cap and white opaque body, size '4' hard gelatin capsules imprinted with 'H' on cap and 'L1' on body, filled with off white to pale yellow color powder.</p> <p>Bottles of 28 NDC 31722-0257-28 Bottles of 100 NDC 31722-0257-01</p> <p>Lenalidomide Capsules 5 mg: White opaque cap and white opaque body, size '2' hard gelatin capsules imprinted with 'H' on cap and 'L2' on body, filled with off white to pale yellow color powder.</p> <p>Bottles of 28 NDC 31722-0258-28 Bottles of 100 NDC 31722-0258-01</p> <p>Lenalidomide Capsules 10 mg: Orange opaque cap and white opaque body, size '0' hard gelatin capsules imprinted with 'H' on cap and 'L4' on body, filled with</p>



	<p>off white to pale yellow color powder.</p> <p>Bottles of 28 NDC 31722-0259-28 Bottles of 100 NDC 31722-0259-01</p> <p>Lenalidomide Capsules 15 mg: Red opaque cap and white opaque body, size '0' hard gelatin capsules imprinted with 'H' on cap and 'L5' on body, filled with off white to pale yellow color powder.</p> <p>Bottles of 21 NDC 31722-0260-21 Bottles of 100 NDC 31722-0260-01</p> <p>Lenalidomide Capsules 20 mg: Brown opaque cap and white opaque body, size '0' hard gelatin capsules imprinted with 'H' on cap and 'L6' on body, filled with off white to pale yellow color powder.</p> <p>Bottles of 21 NDC 31722-0261-21 Bottles of 100 NDC 31722-0261-01</p> <p>Lenalidomide Capsules 25 mg: White opaque cap and white opaque body, size '0' hard gelatin capsules imprinted with 'H' on cap and 'L7' on body, filled with off white to pale yellow color powder.</p> <p>Bottles of 21 NDC 31722-0262-21 Bottles of 100 NDC 31722-0262-01</p>
--	---

**Section 10: Stability and Reactivity**

<b>Reactivity</b>	No information identified.
<b>Chemical stability</b>	Chemically stable; pharmacological stability not guaranteed beyond expiration date imprinted on

	package.
<b>Possibility of Hazardous Reactions</b>	Not expected to occur.
<b>Conditions to Avoid</b>	Avoid extreme temperatures.
<b>Incompatible materials</b>	Strong oxidizers.
<b>Hazardous Decomposition products</b>	No information identified.

### Section 11: Toxicological Information

#### Information on toxicological effects

**Route of entry:** May be absorbed by inhalation, skin or eye contact and ingestion.

Acute toxicity

Compound	Type	Route	Species	Dose
Cellulose	LC50	Inhalation	Rat	>5800 mg/m <sup>3</sup> /4h
	LD50	Oral	Rat	>5000 mg/kg
	LD50	Dermal	Rabbit	>2000 mg/kg
Lenalidomide	Minimum	Oral	Rat/Mouse	>2000 mg/kg
	Lethal Dose			
	Minimum	Intravenous	Rat/Mouse	>40 mg/kg
Magnesium Stearate	Lethal Dose			
	LC50	Inhalation	Rat	>2000 mg/m <sup>3</sup>

**Irritation/Corrosion** No data available.

**Sensitization** No data available.

**STOT-single exposure** No data available.

### Section 12: Ecological Information

<b>Toxicity</b>	Avoid release into the environment.
<b>Persistence and Degradability</b>	No data available.
<b>Bioaccumulative Potential</b>	No data available.
<b>Mobility in Soil</b>	No data available.
<b>Results of PBT and vPvB assessment:</b>	Not performed.
<b>Other adverse effects</b>	No data available.



### Section 13: Disposal Considerations

<b>Waste treatment methods</b>	Dispose of wastes by appropriately permitted chemical waste incinerator in accordance to prescribed federal, state, and local guidelines. Do not send down the drain or flush down the toilet. All wastes containing the material should be properly labeled. Rinse waters resulting from spill cleanups should be discharged in an environmentally safe manner, e.g., appropriately permitted municipal or onsite wastewater treatment facility.
--------------------------------	---

### Section 14: Transport Information

<b>Transport:</b>	This product/mixture is not regulated as a hazardous material/dangerous good under EU ADR/RID, US DOT, Canada TDG, IATA, or IMDG.
<b>UN number</b>	None assigned.
<b>UN proper shipping name</b>	None assigned.
<b>Transport hazard classes and packing group</b>	None assigned.
<b>Environmental hazards</b>	Based on the available data, this product/mixture is not regulated as an environmental hazard or a marine pollutant.
<b>Special precautions for users</b>	Due to lack of data, avoid release to the environment.
<b>Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code</b>	Not applicable.

### Section 15: Regulatory Information

This SDS generally complies with the requirements listed under current guidelines in the US, EU and Canada. Consult your local or regional authorities for more information.



## Section 16: Other Information

**Issue Date : 15-03-2023**

**Version : 01**

**Further information**

**Revision date: 15-03-2023**

**Revision note: 01 – Excipient details included in section 3.**

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Hetero Labs Limited shall not be held liable for any damage resulting from handling or from contact with the above product. Hetero Labs Limited reserves the right to revise this SDS.